News
MCRB
0.5599
-4.16%
-0.0243
Weekly Report: what happened at MCRB last week (0408-0412)?
Weekly Report · 5d ago
SERES THERAPEUTICS INC: CLINICAL DATA READOUT EXPECTED END OF Q3 2024
Reuters · 04/09 11:00
SERES THERAPEUTICS ANNOUNCES COMPLETION OF PATIENT ENROLLMENT FOR SER-155 PHASE 1B COHORT 2 CLINICAL TRIAL IN ALLOGENIC HSCT
Reuters · 04/09 11:00
Weekly Report: what happened at MCRB last week (0401-0405)?
Weekly Report · 04/08 09:06
Weekly Report: what happened at MCRB last week (0325-0329)?
Weekly Report · 04/01 09:06
Seres Therapeutics Inc: Initial statement of beneficial ownership of securities
Press release · 03/27 21:12
Weekly Report: what happened at MCRB last week (0318-0322)?
Weekly Report · 03/25 09:06
Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet
Seres Therapeutics, Inc. Share price has dived 30% in the last 30 days. The company has a price-to-sales ratio of 0.9x. Its revenue growth over the last three years has been superior to most other companies. However, the company's revenue growth is expected to decline over the next three years. The low P/S ratio may look like a good buying opportunity for Seres TherAPEutics.
Simply Wall St · 03/23 12:23
Weekly Report: what happened at MCRB last week (0311-0315)?
Weekly Report · 03/18 09:06
Institutional owners may take dramatic actions as Seres Therapeutics, Inc.'s (NASDAQ:MCRB) recent 25% drop adds to one-year losses
Institutional investors own 44% of Seres Therapeutics, Inc. (NASDAQ:MCRB) The company has a total of 10 investors with a majority of the stock. SeresTherapeutics has a large amount of shares in the company. The company is owned by a group of institutions with a 51% stake in the firm. It is worth looking at the company's ownership of shares to see if insiders are buying or selling. Se restherapeutics saw its value drop by 25% last week.
Simply Wall St · 03/12 12:32
Weekly Report: what happened at MCRB last week (0304-0308)?
Weekly Report · 03/11 09:06
Seres Therapeutics Is Maintained at Outperform by Oppenheimer
Dow Jones · 03/06 14:09
Seres Therapeutics Price Target Cut to $5.00/Share From $9.00 by Oppenheimer
Dow Jones · 03/06 14:09
Oppenheimer Maintains Outperform on Seres Therapeutics, Lowers Price Target to $5
Benzinga · 03/06 13:59
Emerson Electric To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Morgan Stanley boosted the price target for Sea Limited (NYSE:SE) from $47 to $65 on Tuesday. Barclays raised the price targets for Target Corporation and Emerson Electric. Guggenheim boosted Ross Stores, Inc. Price target from $140 to $165. Wells Fargo slashed Twilio's price target to $60.
Benzinga · 03/06 13:00
Oppenheimer Sticks to Its Buy Rating for Seres Therapeutics (MCRB)
TipRanks · 03/06 12:55
Seres Therapeutics Price Target Cut to $8.00/Share From $10.00 by Chardan Capital
Dow Jones · 03/06 12:49
Seres Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 03/06 12:49
Chardan Capital Maintains Buy on Seres Therapeutics, Lowers Price Target to $8
Benzinga · 03/06 12:38
U.S. RESEARCH ROUNDUP-Arrivent Biopharma, Ferguson, Target
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Arrivent Biopharma, Ferguson and Target among companies with revised targets. Ferguson, Target and Box are among the companies with new analyst coverage. Analysts raised their ratings on Arrivent, Ferguson, and Target.
Reuters · 03/06 06:47
More
Webull provides a variety of real-time MCRB stock news. You can receive the latest news about Seres Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About MCRB
Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of Clostridioides difficile infection (CDI) in patients 18 or older following antibacterial treatment for recurrent CDI. Building upon VOWST, it is developing novel microbiome therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, an oral microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to prevent enteric-derived infections and resulting blood stream infections and induce immune tolerance responses to reduce the incidence of GvHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).